To characterize the response of cancer cells and TIICs in melanoma undergoing anti-PD-1 therapy, we collected tumor masses on day 3 after the second anti-PD-1 treatment, and subjected tumor masses to single-cell RNA sequencing (scRNA-seq) (Fig. 6A). Here, PDCD1 is linked to cancer.